Earlier this month, Folium Biosciences submitted a novel food application to the UK Food Standards Agency (FSA) for validation of its hemp-derived, 0.0% THC broad-spectrum cannabidiol (CBD) oil.
Earlier this month, Folium Biosciences (Colorado Springs, CO) submitted a novel food application to the UK Food Standards Agency (FSA) for validation of its hemp-derived, 0.0% THC broad-spectrum cannabidiol (CBD) oil. The application was submitted on behalf of Folium Biosciences Europe B.V. and a consortium of the company’s diverse, UK-based CBD product customer partners in response to the 2020 FSA requirements that all CBD products on the UK market have a novel food application prior to March 21, 2020. CBD food products that do not get regulatory approval prior to this deadline will no longer be able to sell their products in the UK.
“Folium has a long-standing track record for quality, safety, consistency and supply chain transparency that has enabled us to secure approvals from ethical commissions and regulatory bodies around the world – even in countries with stringent cannabinoid regulations, such as Japan, Australia, New Zealand and South America,” said Folium chief scientific officer Vanesa Fernandez, in a press release. “We’re proud to be continuing to demonstrate global CBD leadership as an active participant in the UK’s regulatory advances, and look forward to moving through the novel foods regulatory process next in the EU. It’s in the best interest of everyone in the CBD industry and the end customers we serve to make product quality and compliance our top priority.”
Included in the novel food application are its white-label finished products, its customers’ finished products and its broad spectrum hemp oil water soluble powder. Novel food approval would therefore ensure that all of Folium’s customer partners are able to maintain their market advantage with both white-label and custom formulations.